The management of Venous Thromboembolism in terms of treatments and prevention has been well researched for patients who have been discovered as positive for Factor V Leiden genetic clotting disorder, in either the homozygous or the heterozygous genotype. In fact, the research and development of new agents called Direct oral anticoagulants aim to treat and prevent clotting events while minimizing the risks of bleeding. Although several risk factors have been identified in relation to VTE, Factor V Leiden mutation presents a seemingly higher risk due to its unpredictable incidences of clotting events, even in patients with optimal health characteristics. Yet, we haven’t transitioned to routine testing of the common population for the Factor V Leiden as a preventative measure, rather the focus has been on those at risk due to family history of VTE or if clinical decisions might depend on it, such as the proper choice of contraception for female patients. Additionally, the increased risk of thrombophilia during pregnancy raises concern for proper medical management that would benefit the mother, without harming the baby, at any point of the pregnancy.
Wolf, S. (2020). What are the Most Appropriate Treatments, Preventions and Family Planning Options for Patients with Factor V Leiden?. The Science Journal of the Lander College of Arts and Sciences, 13(2). Retrieved from https://touroscholar.touro.edu/sjlcas/vol13/iss2/4